AGENDIA | MedPath

Agendia's BluePrint Test Shows Promise in Identifying Chemotherapy-Responsive Breast Cancer Subtypes

18 days ago

• New FLEX Study data reveals BluePrint molecular subtyping assay can identify Basal-type tumors among MammaPrint High Risk HR+ HER2- breast cancers that respond better to chemotherapy. • Patients with Basal-type tumors showed higher pathological complete response rates following neoadjuvant chemotherapy compared to those with Luminal B tumors, supporting more personalized treatment approaches. • The findings, to be presented at ESMO Breast Cancer 2025, demonstrate how BluePrint's 80-gene signature provides actionable insights that physicians are using to inform real-world treatment decisions.

MammaPrint Assay Identifies Subgroup Benefiting from Extended Letrozole Therapy in Early-Stage Breast Cancer

5 months ago

A recent study reveals that the MammaPrint genetic assay can identify a subgroup of patients with hormone receptor-positive early-stage breast cancer who may benefit most from extended letrozole therapy. Contrary to initial hypotheses, the benefits were observed in low-risk, not high-risk, patients, suggesting a new direction for personalized treatment strategies.

De-escalated Neoadjuvant Therapy Shows Comparable Survival in HR+/HER2+ Early Breast Cancer

8 months ago

• The WSG-TP-II trial investigated de-escalated neoadjuvant regimens in HR-positive, HER2-positive early breast cancer, comparing endocrine therapy plus trastuzumab/pertuzumab to paclitaxel plus trastuzumab/pertuzumab. • Event-free survival at 5 years was 92.1% with endocrine therapy vs 94.8% with chemotherapy; overall survival was 100% vs 97.9%, indicating comparable long-term outcomes. • The study suggests that endocrine therapy plus dual HER2 blockade can be a safe initial approach, reserving chemotherapy for patients not responding to de-escalated treatment. • The trial demonstrated the feasibility of a 12-week chemotherapy-free de-escalation strategy without compromising survival in early-stage, hormone receptor-positive, HER2-positive breast cancer.